- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| LAKESHORE BIOPHARMA Aktie jetzt für 0€ handeln | |||||
| 24.06. | LakeShore Biopharma Co., Ltd. - 15-12G, Securities registration termination | 5 | SEC Filings | ||
| 24.06. | EQS-News: LAKESHORE BIOPHARMA CO., LTD: LakeShore Biopharma Announces Completion of Going Private Transaction | 391 | EQS Group (EN) | EQS-News: LAKESHORE BIOPHARMA CO., LTD
/ Key word(s): Financial
LakeShore Biopharma Announces Completion of Going Private Transaction 24.06.2026 / 18:13 CET/CEST
The issuer... ► Artikel lesen | |
| 22.06. | LakeShore Biopharma Co., Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 19.06. | EQS-News: LakeShore Biopharma Co., Ltd: LakeShore Biopharma Announces Shareholders' Approval of Merger Agreement | 470 | EQS Group (EN) | EQS-News: LAKESHORE BIOPHARMA CO., LTD
/ Key word(s): Financial
LakeShore Biopharma Announces Shareholders' Approval of Merger Agreement 19.06.2026 / 14:05 CET/CEST
The issuer... ► Artikel lesen | |
| 28.05. | LakeShore Biopharma Co., Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 28.05. | EQS-News: LakeShore Biopharma Co., Ltd: LakeShore Biopharma to Hold Extraordinary General Meeting of Shareholders | 467 | EQS Group (EN) | EQS-News: LAKESHORE BIOPHARMA CO., LTD
/ Key word(s): Financial
LakeShore Biopharma to Hold Extraordinary General Meeting of Shareholders 28.05.2026 / 15:15 CET/CEST
The issuer... ► Artikel lesen | |
| 29.04. | EQS-News: LakeShore Biopharma Co., Ltd: LakeShore Biopharma Enters Into Amended Merger Agreement for Going-Private Transaction | 460 | EQS Group (EN) | EQS-News: LAKESHORE BIOPHARMA CO., LTD
/ Key word(s): Financial
LakeShore Biopharma Enters Into Amended Merger Agreement for Going-Private Transaction 29.04.2026 / 14:03 CET/CEST
The... ► Artikel lesen | |
| 29.04. | LakeShore Biopharma Co., Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 25.03. | LakeShore Biopharma receives reduced buyout offer at $0.06/share | 1 | Investing.com | ||
| 25.03. | LakeShore Biopharma Co., Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 06.02. | LakeShore Biopharma's $0.90 per share going-private deal at risk | 1 | Investing.com | ||
| 06.02. | LakeShore Biopharma Co., Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 29.01. | LakeShore Biopharma Co., Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 30.09.25 | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 30.09.2025 | 1.362 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 30.09.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 30.09.2025ISIN NameCA8875221001 TINKA... ► Artikel lesen | |
| 22.09.25 | LakeShore Biopharma Co., Ltd.: LakeShore Biopharma Announces Transition to OTC Market Following Nasdaq Delisting | 375 | PR Newswire | BEIJING, Sept. 22, 2025 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company... ► Artikel lesen | |
| 12.09.25 | LakeShore Biopharma Co., Ltd.: LakeShore Biopharma Announces Receipt of Delisting Determination Letter from Nasdaq | 991 | PR Newswire | BEIJING, Sept. 12, 2025 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company... ► Artikel lesen | |
| 28.08.25 | LakeShore Biopharma Co., Ltd.: LakeShore Biopharma Announces Receipt of a Revised Preliminary Non-Binding Proposal to Acquire the Company and Formation of Special Committee | 634 | PR Newswire | BEIJING, Aug. 28, 2025 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company... ► Artikel lesen | |
| 18.08.25 | LakeShore Biopharma Co., Ltd.: LakeShore Biopharma Announces Receipt of a Preliminary Non-Binding Proposal to Acquire the Company | 320 | PR Newswire | BEIJING, Aug. 18, 2025 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company... ► Artikel lesen | |
| 31.07.25 | LakeShore Biopharma Co., Ltd.: LakeShore Biopharma Announces Fiscal Year 2025 Financial Results | 216 | PR Newswire | Total revenue reached RMB615.0 million, representing 7.2% year-over-year growth
Gross profit rose to RMB507.2 million, up 11.3% year-over-year
Gross margin improved... ► Artikel lesen |
19 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 36,335 | -0,66 % | AKTIEN IM FOKUS 2: Danaher enttäuscht Anleger - Auch Sartorius-Kurs leidet | (neu: Kurse mit Danaher im offiziellen Handel, Analystenstimmen) FRANKFURT/NEW YORK (dpa-AFX) - Der Quartalsbericht von Danaher hat im Diagnostikbereich am Dienstag international eine Welle der Enttäuschung... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 13,680 | +0,15 % | Summit Therapeutics Flags Going Concern Risk Over Cash Needs | ||
| TARSUS PHARMACEUTICALS | 58,66 | 0,00 % | Guggenheim cuts Tarsus Pharmaceuticals stock price target to $89 | ||
| PRAXIS PRECISION MEDICINES | 324,95 | -0,11 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| DYNE THERAPEUTICS | 24,430 | -0,04 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD) | - Priority Review granted; PDUFA target action date set for January 21, 2027 - - Submission for Accelerated Approval based on dystrophin as a surrogate endpoint - - In the registrational expansion... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 134,26 | -0,01 % | Apogee Therapeutics Aktie erreicht Rekordhoch von 134,34 USD | ||
| DISC MEDICINE | 74,12 | 0,00 % | Disc Medicine Inc: Disc Medicine Provides Update from FDA Type A Meeting for Bitopertin in Erythropoietic Protoporphyria | Aligned with the FDA that the Phase 3 APOLLO study, if successful, can serve as the basis for CRL response and could potentially support a traditional approvalOn track for expected CRL response submission... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 52,95 | 0,00 % | Enliven Therapeutics, Inc.: Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants | BURLINGAME, Calif., June 11, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company... ► Artikel lesen | |
| COGENT BIOSCIENCES | 39,740 | -0,05 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) | Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated... ► Artikel lesen | |
| ERASCA | 19,110 | 0,00 % | Erasca, Inc.: Erasca Announces Updated Preliminary Phase 1 Data and Registration-Enabling Plans for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors | At RDE of 32 mg QD, encouraging monotherapy responses with 57% uORR in 2L+ KRAS G12X pancreatic cancer in U.S. trial and median relative dose intensity of 100% Monotherapy has been generally well-tolerated... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 8,690 | 0,00 % | Vir Biotechnology: Abgang des Finanzchefs schickt Aktie auf Talfahrt | ||
| TANGO THERAPEUTICS | 26,630 | 0,00 % | How Much Upside is Left in Tango Therapeutics (TNGX)? Wall Street Analysts Think 49.48% | ||
| EDGEWISE THERAPEUTICS | 40,790 | -0,12 % | Servier completes the acquisition of Edgewise Therapeutics' Muscular Dystrophy Business | Acquisition supports Servier's strategic ambition in rare neurology with sevasemten, a late-stage investigational treatment for Becker and Duchenne muscular dystrophies. The acquired asset... ► Artikel lesen | |
| SIONNA THERAPEUTICS | 45,700 | 0,00 % | Sionna Therapeutics, Inc.: Sionna Therapeutics Completes Enrollment in PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, Added to Standard of Care in Participants with Cystic Fibrosis | WALTHAM, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm... ► Artikel lesen | |
| SCRIBE THERAPEUTICS | 21,860 | +0,97 % | Scribe Therapeutics Inc.: Scribe Therapeutics Announces Pricing of Upsized Initial Public Offering | ALAMEDA, Calif., July 23, 2026 (GLOBE NEWSWIRE) -- Scribe Therapeutics Inc. ("Scribe Therapeutics") (Nasdaq: SCTX), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR... ► Artikel lesen |
Das Unternehmen LAKESHORE BIOPHARMA CO LTD kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,665 Euro.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LAKESHORE BIOPHARMA CO LTD finden Sie auf Wallstreet Online.